JPMorgan analyst Anupam Rama raised the firm’s price target on Cogent Biosciences (COGT) to $44 from $30 and keeps an Overweight rating on the shares. The firm also placed Cogent on “Positive Catalyst Watch” ahead of updates for the company’s lead asset bezuclastinib in the advanced systemic mastocytosis and gastrointestinal stromal tumor studies anticipated by the end of 2025. JPMorgan sees the shares as undervalued into the mid-to-high $20s on the systemic mastocytosis franchise alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Promising Outlook for Cogent Biosciences: Buy Rating Backed by FDA Breakthrough Designation and Strong Phase 3 Trial Prospects
- Cogent Biosciences announces FDA BTD for bezuclastinib
- Cogent Biosciences initiated with a Hold at Stifel
- Cogent Biosciences added to Analyst Current Favorites list at Raymond James
- Cogent Biosciences Signs Lease for New Headquarters